Bild zu Biopharm

METHOD DEVELOPMENT AND VALIDATION

SYMBIOSIS offers the development of new and optimisation of existing methods for all types of therapeutic molecules as well as their validation according to ICH guideline Q2. A validation protocol including acceptance criteria will be compiled or your existing validation protocol is used. Your analytical methods, developed by SYMBIOSIS, can be easily transferred to your labs with the help of our support.

Press

April 2016: 30 Years BIOPHARM

We are proud to announce the 30th anniversary of BIOPHARM GmbH.

September 2013: New Testing Services

As part of our stability and characterization services for mammalian and microbial cell banks we are pleased to inform you that SYMBIOSIS has extended its testing services.

Phage Testing:

For microbial cell lines testing of adventitious parameters, e.g. for bacteriophages is required. Testing is performed on standard hosts or on customized host strains for lytic as well as under inducing conditions for lysogenic phages.

Copy Number Determination:

The (plasmid/gene) copy number is one of the key variables during cell line development. As a stability indicating parameter we offer copy number determination by real-time quantitative PCR which enables us to provide you with specific, reproducible and easy-to-interpret copy number results. Additional methods e.g. capillary electrophoresis can be offered upon request.

Please contact us for more information.

April 22-24, 2013: Successfull FDA Inspection

In April 2013 SYMBIOSIS has successfully completed a FDA inspection reviewing its quality system and facilities. Verbal feedback received from the inspector commented on the excellent quality of the facilities and laboratories of SYMBIOSIS.

 "The successful inspection of our business division SYMBIOSIS is a tremendous form of validation for our team and a result of our constant efforts and investment in our quality systems and laboratories", commented Dr. Florian Wagner, Managing Director of SYMBIOSIS.

17.04.2012: Labor L+S AG and SYMBIOSIS form Exclusive Business Alliance

Bad Bocklet and Heidelberg, Germany, April 17, 2012 - Labor L+S AG, Bad Bocklet and SYMBIOSIS, the newly created business division of BIOPHARM GmbH, Heidelberg, today announced that they have entered into an exclusive business alliance.

As of May 1st, 2012 Labor L+S AG will be able to offer to its customers comprehensive services and solutions in analytical testing of biopharmaceuticals and classical pharmaceuticals exclusively performed by SYMBIOSIS. The business alliance with SYMBIOSIS expands the portfolio of Labor L+S AG and will enable clients of Labor L+S AG to order additional analytical services through a single point of contact, supporting all stages of the drug development life cycle and ensuring highest quality and improved cost and time efficiency for the benefit of its customers.

“Our goal at Labor L+S AG is to continuously extend the range of required services that meet the regulatory and scientific needs of our clients in the pharmaceutical and biotech industry. This business alliance with SYMBIOSIS enhances our ability to exceed client expectations by offering cost effective, innovative analytical services that accelerate the development, production and safety assessment of their pharmaceutical or biopharmaceutical product”, explains Dr. Lothar Bomblies, Member of the Management Board of Labor L+S AG.

Dr. Florian Wagner, CEO of Biopharm GmbH, comments: “We are proud to work together with the market leader in pharmaceutical microbiology in Germany. The continuously changing market demands of the life science industry require an expert partner with a broad range of services. This alliance brings together two well-established players in the German market, forming a powerful and innovative one-stop-shop service provider”.

Download Flyer L+S Additional Services

Bad Bocklet and Heidelberg, Germany, April 17, 2012 - Labor L+S AG, Bad Bocklet and SYMBIOSIS, the newly created business division of BIOPHARM GmbH, Heidelberg, today announced that they have entered into an exclusive business alliance.

As of May 1st, 2012 Labor L+S AG will be able to offer to its customers comprehensive services and solutions in analytical testing of biopharmaceuticals and classical pharmaceuticals exclusively performed by SYMBIOSIS. The business alliance with SYMBIOSIS expands the portfolio of Labor L+S AG and will enable clients of Labor L+S AG to order additional analytical services through a single point of contact, supporting all stages of the drug development life cycle and ensuring highest quality and improved cost and time efficiency for the benefit of its customers.

Our goal at Labor L+S AG is to continuously extend the range of required services that meet the regulatory and scientific needs of our clients in the pharmaceutical and biotech industry. This business alliance with SYMBIOSIS enhances our ability to exceed client expectations by offering cost effective, innovative analytical services that accelerate the development, production and safety assessment of their pharmaceutical or biopharmaceutical product”, explains Dr. Lothar Bomblies, Member of the Management Board of Labor L+S AG.

Dr. Florian Wagner, CEO of Biopharm GmbH, comments: “We are proud to work together with the market leader in pharmaceutical microbiology in Germany. The continuously changing market demands of the life science industry require an expert partner with a broad range of services. This alliance brings together two well-established players in the German market, forming a powerful and innovative one-stop-shop service provider”.

01.11.2011: SYMBIOSIS is now part of Biopharm GmbH

SYMBIOSIS – The Analytical Company – is the newly created business division of Biopharm GmbH offering services and solutions for biopharmaceuticals and classical pharmaceuticals. SYMBIOSIS integrates the extensive experience and expertise of Biopharm GmbH in analytical services of more than 25 years combined with a customer-focused approach driven by excellence in process, communication and quality. GMP and GLP certified we operate according to the highest quality assurance standards. Fact sheet SYMBIOSIS

Events

2014 BIO International Convention, June 23-26 2014, San Diego (USA)

The world’s most influential biotech meeting is coming to San Diego, June 23 – 26, offering four days of targeted networking, insights and partnering opportunities. Register for BIO 2014 at convention.bio.org.

Meet SYMBIOSIS at Booth 4523 (Hall A - Germany Pavilion - click here for the location on the convention map) or have a one-to-one meeting in the partnering booth with our Research & Development branch BIOPHARM GmbH.

BIO International Convention, April 22 – 25 2013, Chicago (USA)

The global event for Biotechnology - With more than 15,000 attendees, 4000 participating companies and more than 1700 exhibiting companies the 2013 Bio Convention will be the world's leading Biotech forum. Come and visit our SYMBIOSIS booth 4022-2 at the German Pavillon where we will present our latest techniques and technologies in the field of analytical services.

Come and join us in a private session at the BIO Business Forum, becoming the industry's largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. Powered by BIO's One-on-One Partnering System, the Business Forum fosters the opportunity to initiate business contacts in a friendly environment and schedule meetings prior to the conference. To take advantage of partnering and to make an appointment with us please register with the BIO Business Forum. The One-on-One partnering system is scheduled to open in February 2013.

ICSE/CPhl Worldwide, 9-11 Oct 2012, Madrid

The CPhl/ICSE in Madrid has - once again - been the world's leading pharmaceutical networking event with over 30,000 attendees from 140 countries.  SYMBIOSIS - The Analytical Company - has presented its portfolio of customer-oriented methods and solutions especially focusing on biopharmaceuticals at booth 10C83 right next to the Speaker's Corner.

The presentation held by Dr. Frank Plöger on “The use of bioassays for release and characterization of biopharmaceuticals” has been one of the key speeches at this year’s venue and highlighted in the CPhl/ICSE digital media channel. We would like to thank all our customers and visitors visiting us in Madrid for the interesting and fruitful discussions and meetings we had together.

We are looking forward to meeting with you again at CPhl/ICSE 2013 in Frankfurt !

BIO International Convention, June 18-21 2012, Boston (USA)

The global event for Biotechnology - With more than 15,000 attendees, 4000 participating companies and more than 1700 exhibiting companies the 2012 Bio Convention will be the world's leading Biotech forum. Come and visit our SYMBIOSIS booth #0714 and BIOPHARM booth #0716 at the German Pavillon where we will present our latest techniques and technologies in the field of analytical services.

Come and join us in a private session at the BIO Business Forum, becoming the industry's largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. Powered by BIO's One-on-One Partnering System, the Business Forum fosters the opportunity to initiate business contacts in a friendly environment and schedule meetings prior to the conference. To take advantage of partnering and to make an appointment with us please register with the BIO Business Forum. The One-on-One partnering system is scheduled to open in April 2012.

Read more here!

Concourse View at BIO 2012 SYMBIOSIS & BIOPHARM booths

BioEurope, 31 Oct - 2 Nov 2011, Düsseldorf

SYMBIOSIS - The Analytical Company - was participating again in the Partnering Meetings at this year's BioEurope in Düsseldorf. With a total of 2,825 attendees from more than 1,596 companies participating in 14,765 one-to-one meetings, 183 company presentations, and 94 international exhibitions on products and technologies the 2012 BioEurope was again of the most outstanding European Biotech fairs. We would like to thank all attendees of the SYMBIOSIS Partnering sessions for their interest in the services and solutions of SYMBIOSIS and the productive meetings we had. See you next year in Hamburg!

ICSE/CPhI Worldwide; 25-27 October 2011

Again, the CPhl/ICSE in Frankfurt has been the world's leading pharmaceutical networking event with over 28,500 attendees from 140 countries.  SYMBIOSIS - The Analytical Company - has for the first time presented its new portfolio of customer-oriented methods and solutions especially focusing on biopharmaceuticals to many visitors from all over the world. We would like to thank all our customers and visitors visiting us in Frankfurt for the interesting and fruitful discussions and meetings we had together. We are looking forward to meeting with you again at CPhl/ICSE 2012 in Madrid !

Dr. Florian Wagner, Rainer Ries, Dr. Frank Plöger, Jennifer Heisler

Contact

For more information contact us at:

Icon Phone +49 (0) 6221 53 83-0
Icon Mail info@symbiosis.de